NCT04412044View on ClinicalTrials.gov

Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

May 1, 2018

Study Completion Date

March 1, 2019

Conditions
Asthma
Interventions
DRUG

Mepolizumab Injection [Nucala]

Patients receive monthly injection with 100 mg mepolizumab

All Listed Sponsors
lead

KU Leuven

OTHER

NCT04412044 - Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines | Biotech Hunter | Biotech Hunter